Experience of Octreotide Therapy for Hyperinsulinemic Hypoglycemia in Neonates Born Small for Gestational Age: A Case Series | Zendy

Si-nian Pan | Zendy; Min Zhang | Zendy; Yinya Li | Zendy

Open Access

Experience of Octreotide Therapy for Hyperinsulinemic Hypoglycemia in Neonates Born Small for Gestational Age: A Case Series

Author(s) -

Si-nian Pan,

Min Zhang,

Yinya Li

Publication year - 2015

Publication title -

hormone research in paediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.816

H-Index - 89

eISSN - 1663-2826

pISSN - 1663-2818

DOI - 10.1159/000441108

Subject(s) - octreotide , medicine , hyperinsulinemic hypoglycemia , small for gestational age , hypoglycemia , pediatrics , diazoxide , neonatal hypoglycemia , gestational age , adverse effect , glycemic , gastroenterology , somatostatin , gestation , pregnancy , insulin , gestational diabetes , biology , genetics

Hyperinsulinemic hypoglycemia (HH) is common in small-for-gestational-age (SGA) neonates. Diazoxide is often used as the first-line medication for HH in SGA neonates. Unfortunately, diazoxide is not authorized in China. We examined the effectiveness of octreotide as an alternative therapy to treat HH in SGA neonates. There is limited data on the use of octreotide in HH of SGA neonates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research